Death · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE DECANOATE changes death compared with PLACEBO (very low certainty).
1 finding from 1 review
Global state: No clinically important change (as defined by the original studies) · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE DECANOATE changes no clinically important global change compared with ORAL NEUROLEPTICS (very low certainty).
1 finding from 1 review
Hospital admission ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early · patients with schizophrenia
FLUPHENAZINE DECANOATE showed no clear difference in leaving the study early compared with ORAL NEUROLEPTICS (low certainty).
1 finding from 1 review
Mental state: psychopathology Total endpoint data, BPRS (higher score = worse, scale from: 0‐126) · patients with schizophrenia
1 finding from 1 review
Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE DECANOATE changes extrapyramidal adverse effects ‐ general compared with ORAL NEUROLEPTICS (very low certainty).
1 finding from 1 review
Relapse · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE DECANOATE changes relapse compared with PLACEBO (very low certainty).
1 finding from 1 review
Clinically significant change in global state ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospital admission ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE DECANOATE changes leaving the study early compared with PLACEBO (very low certainty).
1 finding from 1 review
Mental state · patients with schizophrenia
1 finding from 1 review
Extrapyramidal adverse effects ‐ tardive dyskinesia · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE DECANOATE changes extrapyramidal adverse effects ‐ tardive dyskinesia compared with PLACEBO (very low certainty).
1 finding from 1 review
Death ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE DECANOATE changes relapse compared with ORAL NEUROLEPTICS (very low certainty).
1 finding from 1 review
Weight (kg) · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
1 finding from 1 review
Global state: Changing dose because of deterioration ‐ switching to haloperidol decanoate from fluphenazine decanoate · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN showed no clear difference in global state: Changing dose because of deterioration ‐ switching to… compared with CONTINUATION ON PREVIOUS REGIMEN: 1a. DIFFERENT DEPOT from… (low certainty).
1 finding from 1 review
Mental state: Deteriorated ‐ switching to haloperidol decanoate from fluphenazine decanoate · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN showed no clear difference in mental state: Deteriorated ‐ switching to haloperidol decanoate from… compared with CONTINUATION ON PREVIOUS REGIMEN: 1a. DIFFERENT DEPOT from… (low certainty).
1 finding from 1 review
Death ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE DECANAOTE changes relapse compared with FLUPHENAZINE ENANTHATE (very low certainty).
1 finding from 1 review
Clinically significant change in global state ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found